Skip to content

Insights into the pathophysiology of HAshimoto’s Thyroiditis: Assessing Residual thyroid cApacity & the role of the gut Microbiome in thyroid hormone metabolism

Insights into the pathophysiology of HAshimoto’s Thyroiditis: Assessing Residual thyroid cApacity & the role of the gut Microbiome in thyroid hormone metabolism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22728
Enrollment
20
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subclinical hypothyroidism

Interventions

rTSH injections for residual thyroid function. Moreover, one week with oral metronidazole (500 mg twice daily) plus ciprofloxacin (500 mg once daily), plus oral vancomycine (500mg four times daily).

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy controls: - Caucasian - 35 – 70 years - BMI 18 – 30 kg/m2 - Able to give informed consent subclinical hypothyroidism: - Caucasian - 35 – 70 years - BMI 18 – 30 kg/m2 - Able to give informed consent - Recent diagnosis of subclinical hypothyroidism: TSH = 10 mU/L, FT4 within normal range and anti-TPO positive

Exclusion criteria

Exclusion criteria: For all subjects: - Use of any medication including levothyroxine, proton pump inhibitors, antibiotics and pro-/ probiotics in the past three months - Diagnosis or symptoms of other autoimmune disease (e.g. T1D, coeliac, rheumatoid arthritis or inflammatory bowel disease like Crohn and colitis ulcerosa) - History of cholecystectomy - Smoking or illicit drug use (MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period - Pregnant or lactating women - Previous intestinal (e.g., bowel resection/reconstruction) surgery - Chronic illness (including a known history of heart failure, renal failure (eGFR <30 ml/min), pulmonary disease, gastrointestinal disorders, or hematologic diseases), or other inflammatory diseases

Design outcomes

Primary

MeasureTime frame
To assess and compare the difference in thyroid gland secretion capacity by measuring maximal FT4 and FT3 response upon intramuscular administration of 0.9mg Thyrogen assessed by AUC0-48hours in subclinical hypothyroid subjects and healthy controls after thyroid stimulation and before and after a short term antibiotics course.

Secondary

MeasureTime frame
Secondary objectives will be influence of gut microbiome on thyroid hormone metabolism and effect of thyroid hormone stimulation on inflammatory status after thyroid stimulation and before and after a short term antibiotics course. - Gut microbiome composition: - To assess and compare changes in the gut microbiome composition between SCT subjects and healthy controls at baseline. - In addition, microbiota composition (and their plasma metabolites) will be determined and compared upon thyroid hormone stimulation and before and after a short term oral antibiotics course. - Thyroid hormone metabolism: - To assess and compare changes of fecal excretion of T4 and T3 in SCT subjects and healthy controls before and after thyroid hormone stimulation. - In addition, we will determine changes of fecal excretion of T4 and T3 before and after a short term antibiotics course. - Quality of life will be determined by ThyPro questionnaire - Immunologic parameters: based on FACS on peripheral blood mononuclear cells (Th1, Th2, Th17, Treg, B cells), cytokines and markers of thyroid autoimmunity (anti-TPO antibodies) in SCT subjects as compared to healthy controls at 0h, 5h and 48h after thyroid stimulation and before and after a short term antibiotics course. - Intestinal transit time - Evaluate the differences of intestinal transit time as assessed by radiopaque makers between SCT subjects and healthy controls.

Contacts

Public Contactmax nieuwdorp

AMC

m.nieuwdorp@amsterdamumc.nl0031 20 5666612

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)